I am a named inventor on the following 22 United States patents:

U.S. Patent #5,512,457 – Cytokine designated Elk ligand
U.S. Patent #5,627,267 – Cytokine designated Elk ligand
U.S. Patent #5,670,625 – Elk ligand fusion proteins
U.S. Patent #5,728,813 – Antibodies directed against Elk ligand
U.S. Patent #5,554,512 – Ligands for Flt3 receptors
U.S. Patent #5,843,423 – Flt3 ligand stimulation of hematopoietic cells
U.S. Patent #6,190,655 – Flt3 ligand uses for exogenous gene transfer
U.S. Patent #6,540,992 – Methods for using elk-L to enhance neuronal survival
U.S. Patent #6,555,520 – Human TSLP DNA and polypeptides
U.S. Patent #6,630,143 – Antibodies against flt3 ligand
U.S. Patent #6,632,424 – Human flt3 ligand
U.S. Patent #6,762,030 – Ligand for CD7, and methods for use thereof
U.S. Patent #6,919,206 – Medium containing flt3 ligand for culturing hematopoietic cells
U.S. Patent #6,994,989 – FLK-1 binding proteins
U.S. Patent #7,041,282 – Ligands for flt3 receptors
U.S. Patent #7,045,128 – Antibodies against flt3 ligand
U.S. Patent #7,288,633 – Modified human thymic stromal lymphopoietin
U.S. Patent #7,294,331 – Methods of using flt3-ligand in hematopoietic cell transplantation
U.S. Patent #7,304,144 – Antibodies binding to human TSLP polypeptides
U.S. Patent #7,329,740 – Flk-1 binding protein
U.S. Patent #7,405,058 – Human TSLP polypeptides
U.S. Patent #7,709,217 – Modified human thymic stromal lymphopoietin

Pending (published) patent applications:
Application #20050058622 - Methods of using flt3-ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
Application #20060014252 - Flk-1 binding protein
Application #20060223754 - Human TSLP polynucleotides
Application #20070207164 - Methods of stimulating hematopoietic cells with flt3-ligand
Application #20070218523 - Modified human thymic stromal lymphopoietin
Application #20080188643 - Modified human thymic stromal lymphopoietin
Application #20090075886 - Dendritic cell stimulatory factor
Application #20090017034 - Antibodies that inhibit TSLP activity